Deficiency of nuclear factor-κB c-Rel accelerates the development of autoimmune diabetes in NOD mice

Diabetes

Volumn 65, Issue 8, 2016, Pages 2367-2379

  Ramakrishnan, Parameswaran ^a   Yui, Mary A ^b   Tomalka, Jeffrey A ^a   Majumdar, Devdoot ^b   Parameswaran, Reshmi ^a   Baltimore, David ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b California Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR REL; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; GENE EXPRESSION; HEMATOPOIETIC CELL; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PANCREATIC LYMPH NODE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; ANIMAL; C57BL MOUSE; DEFICIENCY; GENETICS; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; DIABETES MELLITUS, TYPE 1; FORKHEAD TRANSCRIPTION FACTORS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; NF-KAPPA B; PANCREAS; PROTO-ONCOGENE PROTEINS C-REL; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY;

EID: 84980349599     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1607     Document Type: Article

References (50)

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383:69-82
2. Castaño L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990;8:647-679
3. Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am 2010;39:625-640
4. Tsai S, Shameli A, Santamaria P. CD8+ T cells in type 1 diabetes. Adv Immunol 2008;100:79-124
5. Mallone R, van Endert P. T cells in the pathogenesis of type 1 diabetes. Curr Diab Rep 2008;8:101-106
6. Phillips JM, Parish NM, Raine T, et al. Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations. Rev Diabet Stud 2009;6:97-103
7. Wållberg M, Cooke A. Immune mechanisms in type 1 diabetes. Trends Immunol 2013;34:583-591
8. Oh H, Ghosh S. NF-κB: roles and regulation in different CD4(+) T-cell subsets. Immunol Rev 2013;252:41-51
9. Hori S. c-Rel: a pioneer in directing regulatory T-cell lineage commitment? Eur J Immunol 2010;40:664-667
10. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005;5:472-484
11. Baltimore D. NF-κB is 25. Nat Immunol 2011;12:683-685
12. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab 2011;13:11-22
13. Zhao Y, Krishnamurthy B, Mollah ZU, Kay TW, Thomas HE. NF-κB in type 1 diabetes. Inflamm Allergy Drug Targets 2011;10:208-217
14. Ramakrishnan P, Kahn DA, Baltimore D. Anti-apoptotic effect of hyperglycemia can allow survival of potentially autoreactive T cells. Cell Death Differ 2011;18:690-699
15. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
16. Gilmore TD, Gerondakis S. The c-Rel transcription factor in development and disease. Genes Cancer 2011;2:695-711
17. Hilliard BA, Mason N, Xu L, et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002;110:843-850
18. Chen G, Hardy K, Bunting K, Daley S, Ma L, Shannon MF. Regulation of the IL-21 gene by the NF-κB transcription factor c-Rel. J Immunol 2010;185:2350-2359
19. O'Reilly LA, Hughes P, Lin A, et al. Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation. Cell Death Differ 2015;22:767-778
20. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000;105:1799-1806
21. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, et al. Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol 2003;171:4886-4892
22. Long M, Park SG, Strickland I, Hayden MS, Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009;31:921-931
23. Ruan Q, Kameswaran V, Tone Y, et al. Development of Foxp3(+) regulatory T cells is driven by the c-Rel enhanceosome. Immunity 2009;31:932-940
24. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-485
25. Ramakrishnan P, Baltimore D. Sam68 is required for both NF-κB activation and apoptosis signaling by the TNF receptor. Mol Cell 2011;43:167-179
26. Ramakrishnan P, Clark PM, Mason DE, Peters EC, Hsieh-Wilson LC, Baltimore D. Activation of the transcriptional function of the NF-κB protein c-Rel by O-GlcNAc glycosylation. Sci Signal 2013;6:ra75
27. Wakeland E, Morel L, Achey K, Yui M, Longmate J. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 1997;18: 472-477
28. Isomura I, Palmer S, Grumont RJ, et al. c-Rel is required for the development of thymic Foxp3+ CD4 regulatory T cells [published correction appears in J Exp Med 2010;207:899]. J Exp Med 2009;206:3001-3014
29. Köntgen F, Grumont RJ, Strasser A, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995;9:1965-1977
30. Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, Liou ML. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999;11:361-371
31. Bunting K, Rao S, Hardy K, et al. Genome-wide analysis of gene expression in T cells to identify targets of the NF-kappa B transcription factor c-Rel. J Immunol 2007;178:7097-7109
32. Tumang JR, Hsia CY, Tian W, Bromberg JF, Liou HC. IL-6 rescues the hyporesponsiveness of c-Rel deficient B cells independent of Bcl-xL, Mcl-1, and Bcl-2. Cell Immunol 2002;217:47-57
33. Visekruna A, Huber M, Hellhund A, et al. c-Rel is crucial for the induction of Foxp3(+) regulatory CD4(+) T cells but not T(H)17 cells. Eur J Immunol 2010;40: 671-676
34. Emamaullee JA, Davis J, Merani S, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009;58:1302-1311
35. Jeker LT, Bour-Jordan H, Bluestone JA. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med 2012;2: a007807
36. Valéro R, Baron ML, Guérin S, et al. A defective NF-kappa B/RelB pathway in autoimmune-prone New Zealand black mice is associated with inefficient expansion of thymocyte and dendritic cells. J Immunol 2002;169:185-192
37. Zhu M, Chin RK, Christiansen PA, et al. NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest 2006;116:2964-2971
38. Huang DB, Chen YQ, Ruetsche M, Phelps CB, Ghosh G. X-ray crystal structure of proto-oncogene product c-Rel bound to the CD28 response element of IL-2. Structure 2001;9:669-678
39. Bunting K, Wang J, Shannon MF. Control of interleukin-2 gene transcription: a paradigm for inducible, tissue-specific gene expression. Vitam Horm 2006;74: 105-145
40. Sharma R, Fu SM, Ju ST. IL-2: a two-faced master regulator of autoimmunity. J Autoimmun 2011;36:91-97
41. Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes. Curr Diab Rep 2014;14:553
42. Wang J, Wicker LS, Santamaria P. IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. Semin Immunol 2009;21: 363-371
43. Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. J Immunol 2013; 190:1567-1575
44. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 2005;202:1387-1397
45. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009;31:654-664
46. You S, Belghith M, Cobbold S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005;54:1415-1422
47. D'Alise AM, Auyeung V, Feuerer M, et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A 2008;105: 19857-19862
48. Tritt M, Sgouroudis E, d'Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008;57:113-123
49. Mokhtari D, Barbu A, Mehmeti I, Vercamer C, Welsh N. Overexpression of the nuclear factor-κB subunit c-Rel protects against human islet cell death in vitro. Am J Physiol Endocrinol Metab 2009;297:E1067-E1077
50. Kim S, Millet I, Kim HS, et al. NF-kappa B prevents beta cell death and autoimmune diabetes in NOD mice. Proc Natl Acad Sci U S A 2007;104:1913-1918